Summit Therapeutics Inc. Proceeds from Issuance of Private Placement
Summit Therapeutics Inc. (SMMT) reported Proceeds from Issuance of Private Placement of $500.04 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfPrivatePlacement · last filed 2026-02-23
- Summit Therapeutics Inc. proceeds from issuance of private placement for the quarter ending 2025-12-31 was $500.04M.
- Summit Therapeutics Inc. proceeds from issuance of private placement for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Summit Therapeutics Inc. proceeds from issuance of private placement for the quarter ending 2024-12-31 was -$101.00K, a 102.02% decline year-over-year.
- Summit Therapeutics Inc. proceeds from issuance of private placement for the quarter ending 2024-09-30 was $234.96M.
- Summit Therapeutics Inc. proceeds from issuance of private placement for fiscal 2025 was $500.04M, a 14.99% increase from fiscal 2024.
- Summit Therapeutics Inc. proceeds from issuance of private placement for fiscal 2024 was $434.86M, a 8597.20% increase from fiscal 2023.
- Summit Therapeutics Inc. proceeds from issuance of private placement for fiscal 2023 was $5.00M.
- Summit Therapeutics Inc. proceeds from issuance of private placement for fiscal 2022 was $0.00.
| Period end | Proceeds from Issuance of Private Placement 3 month | Proceeds from Issuance of Private Placement 6 month | Proceeds from Issuance of Private Placement 9 month | Proceeds from Issuance of Private Placement 12 month |
|---|---|---|---|---|
| 2025-12-31 | $500.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $500.04M derived: sum of 2 quarters · filed 2026-02-23 | $500.04M 10-K · filed 2026-02-23 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-20 | $0.00 10-Q · filed 2025-10-20 | ||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-11 | |||
| 2024-12-31 | -$101.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $234.86M derived: sum of 2 quarters · filed 2026-02-23 | $434.86M 10-K · filed 2026-02-23 | |
| 2024-09-30 | $234.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-20 | $434.96M 10-Q · filed 2025-10-20 | ||
| 2024-06-30 | $200.00M 10-Q · filed 2025-08-11 | |||
| 2023-12-31 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $5.00M derived: sum of 2 quarters · filed 2026-02-23 | $5.00M 10-K · filed 2026-02-23 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $0.00 10-Q · filed 2024-10-30 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-06 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |